Treatment Approaches in RET Fusion + NSCLC

 

ecancer
H

ESMO 2023 Insights: "LIBRETTO-431 Phase 3 Study of 1L Selpercatinib vs. Chemo & Pembro in RET Fusion+ NSCLC"

By ecancer FEATURING Herbert Loong
By ecancer FEATURING Herbert Loong
267 views
October 27, 2023
0 Comments
Login to view comments. Click here to Login
Treatment Approaches in RET Fusion + NSCLC
09:52
Lorenzo Belluomini

Selpercatinib in Patients With RET Fusion-Positive NSCLC: Where Are …

26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
21:23
2023 Evolution Conference

Comprehensive Genomic Profiling: Why Aren't We Doing It?

Feat. J. Meisel
27:04
Fengting Yan

Cancer Screening Molecular Tools

06:44
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "The Impact of PET-CT Brain MRI for Metasta…

Feat. W. Liang
19:17
Total Health

Case-Based Clinical Updates in NSCLC: 63 y/o With RET-Altered Disease

Feat. L. Raez, M. Dietrich, C. Hoberg
06:42
ecancer

ESMO 2023 Insights: "LIBRETTO-431 Phase 3 Study of 1L Selpercat…

Feat. H. Loong
14:29
Total Health

Updates on Universal Comprehensive Genomic Profiling & Treatment…

Feat. R. Salgia
21:36
Total Health

Targeted Therapies in NSCLC - Best of Lung 2023

Feat. J. Schneider
20:52
Total Health

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Feat. T. Boyle